azenosertib

Phase 3

Zentalis Pharmaceuticals, Inc. (ZNTL)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

ZNTLPhase 2$209M

Azenosertib Phase 2 Est. Readout

azenosertib• High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer25

Jan 2027~Estimated

CT.gov

00%

Dec '26

ZNTLPhase 2$209M

azenosertib Phase 2 Est. Readout (DENALI)

azenosertib• High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer310

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

1 competitor in High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

View Full Landscape

Drug Information

Target Indication

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical Trial

NCT05128825

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ZNTL

Zentalis Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ZN-d5Phase 2

Amyloidosis

NiraparibPhase 2

Ovarian Cancer

ZN-c3Phase 2

Uterine Serous Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts